Ming Ding1, Shilpa N Bhupathiraju, Ambika Satija, Rob M van Dam, Frank B Hu. 1. Departments of Nutrition (M.D., S.N.B., A.S., R.M.v.D., F.B.H.) and Epidemiology (F.B.H.), Harvard School of Public Health, Boston, MA; Saw Swee Hock School of Public Health and Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore (R.M.v.D.); and Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (F.B.H.).
Abstract
BACKGROUND: Considerable controversy exists on the association between coffee consumption and cardiovascular disease (CVD) risk. A meta-analysis was performed to assess the dose-response relationship of long-term coffee consumption with CVD risk. METHODS AND RESULTS: PubMed and EMBASE were searched for prospective cohort studies of the relationship between coffee consumption and CVD risk, which included coronary heart disease, stroke, heart failure, and CVD mortality. Thirty-six studies were included with 1 279 804 participants and 36 352 CVD cases. A nonlinear relationship of coffee consumption with CVD risk was identified (P for heterogeneity=0.09, P for trend <0.001, P for nonlinearity <0.001). Compared with the lowest category of coffee consumption (median, 0 cups per day), the relative risk of CVD was 0.95 (95% confidence interval, 0.87-1.03) for the highest category (median, 5 cups per day) category, 0.85 (95% confidence interval, 0.80-0.90) for the second highest category (median, 3.5 cups per day), and 0.89 (95% confidence interval, 0.84-0.94) for the third highest category (median, 1.5 cups per day). Looking at separate outcomes, coffee consumption was nonlinearly associated with both coronary heart disease (P for heterogeneity=0.001, P for trend <0.001, P for nonlinearity <0.001) and stroke (P for heterogeneity=0.07, P for trend <0.001, P for nonlinearity <0.001; P for trend differences >0.05) risks. CONCLUSIONS: A nonlinear association between coffee consumption and CVD risk was observed in this meta-analysis. Moderate coffee consumption was inversely significantly associated with CVD risk, with the lowest CVD risk at 3 to 5 cups per day, and heavy coffee consumption was not associated with elevated CVD risk.
BACKGROUND: Considerable controversy exists on the association between coffee consumption and cardiovascular disease (CVD) risk. A meta-analysis was performed to assess the dose-response relationship of long-term coffee consumption with CVD risk. METHODS AND RESULTS: PubMed and EMBASE were searched for prospective cohort studies of the relationship between coffee consumption and CVD risk, which included coronary heart disease, stroke, heart failure, and CVD mortality. Thirty-six studies were included with 1 279 804 participants and 36 352 CVD cases. A nonlinear relationship of coffee consumption with CVD risk was identified (P for heterogeneity=0.09, P for trend <0.001, P for nonlinearity <0.001). Compared with the lowest category of coffee consumption (median, 0 cups per day), the relative risk of CVD was 0.95 (95% confidence interval, 0.87-1.03) for the highest category (median, 5 cups per day) category, 0.85 (95% confidence interval, 0.80-0.90) for the second highest category (median, 3.5 cups per day), and 0.89 (95% confidence interval, 0.84-0.94) for the third highest category (median, 1.5 cups per day). Looking at separate outcomes, coffee consumption was nonlinearly associated with both coronary heart disease (P for heterogeneity=0.001, P for trend <0.001, P for nonlinearity <0.001) and stroke (P for heterogeneity=0.07, P for trend <0.001, P for nonlinearity <0.001; P for trend differences >0.05) risks. CONCLUSIONS: A nonlinear association between coffee consumption and CVD risk was observed in this meta-analysis. Moderate coffee consumption was inversely significantly associated with CVD risk, with the lowest CVD risk at 3 to 5 cups per day, and heavy coffee consumption was not associated with elevated CVD risk.
Authors: Chris M Papamichael; Konstantinos A Aznaouridis; Emmanouil N Karatzis; Kalliopi N Karatzi; Kimon S Stamatelopoulos; Georgia Vamvakou; John P Lekakis; Myron E Mavrikakis Journal: Clin Sci (Lond) Date: 2005-07 Impact factor: 6.124
Authors: James A Greenberg; Christopher C Dunbar; Roseanne Schnoll; Rodamanthos Kokolis; Spyro Kokolis; John Kassotis Journal: Am J Clin Nutr Date: 2007-02 Impact factor: 7.045
Authors: Erikka Loftfield; Neal D Freedman; Barry I Graubard; Kristin A Guertin; Amanda Black; Wen-Yi Huang; Fatma M Shebl; Susan T Mayne; Rashmi Sinha Journal: Am J Epidemiol Date: 2015-11-27 Impact factor: 4.897
Authors: Erikka Loftfield; Meredith S Shiels; Barry I Graubard; Hormuzd A Katki; Anil K Chaturvedi; Britton Trabert; Ligia A Pinto; Troy J Kemp; Fatma M Shebl; Susan T Mayne; Nicolas Wentzensen; Mark P Purdue; Allan Hildesheim; Rashmi Sinha; Neal D Freedman Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-05-21 Impact factor: 4.254
Authors: Giuseppe Grosso; Agnieszka Micek; Justyna Godos; Salvatore Sciacca; Andrzej Pajak; Miguel A Martínez-González; Edward L Giovannucci; Fabio Galvano Journal: Eur J Epidemiol Date: 2016-10-03 Impact factor: 8.082
Authors: Ming Ding; Ambika Satija; Shilpa N Bhupathiraju; Yang Hu; Qi Sun; Jiali Han; Esther Lopez-Garcia; Walter Willett; Rob M van Dam; Frank B Hu Journal: Circulation Date: 2015-11-16 Impact factor: 29.690